Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the efficacy of a serotonin receptor (5-HT(3)) antagonist in the treatment of fibromyalgia (FM) in a prospective, randomized, double-blind, placebo-controlled, multicentre trial. METHODS: Twenty-one female patients (age 21-63 years) with FM according to the American College of Rheumatology classification criteria for FM were assigned randomly to either a placebo group or to receive a daily intravenous bolus injection of 5 mg tropisetron for 5 days. RESULTS: In patients receiving tropisetron, the visual analogue scale (VAS) score for pain decreased by 28.9 compared with a decrease of 6.8 in the placebo group [probability (p)=0.063; effect size: 0.794]. Similar results were obtained using a body diagram pain score as a secondary efficacy parameter: mean pain reduction was 27.2 in the tropisetron group, versus 2.8 in the placebo group (p=0.038; effect size: 0.902). CONCLUSION: 5-HT(3) receptor antagonists provide significant pain relief for a group of FM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The West Haven-Yale Multidimensional Pain Inventory (WHYMPI)
Kerns, R. D., Turk, D. C., & Rudy, T. E. (1985) · Pain · doi:10.1016/0304-3959(85)90004-1 · Cited by 2,128
Elevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome
Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., Lopez, Y., & Mackillip, F. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371106 · Cited by 679
Cited by
Management of fibromyalgia syndrome
Goldenberg, D. L. (2004) · JAMA · doi:10.1001/jama.292.19.2388 · Cited by 850
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752
Self-citationFibromyalgia Pathogenesis and Treatment Options Update
Chinn, S., Caldwell, W., & Gritsenko, K. (2016) · Current Pain and Headache Reports · doi:10.1007/s11916-016-0556-x · Cited by 296
The 5-HT3receptor as a therapeutic target
Thompson, A. J., & Lummis, S. C. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.527 · Cited by 257
Biology and therapy of fibromyalgia. New therapies in fibromyalgia.
Arnold (2006) · Arthritis Research & Therapy · doi:10.1186/ar1971 · Cited by 145
“significant improvement in pain in the tropisetron group compared to placebo [95].”
Result
Metadata
- Authors
- Späth, M., Stratz, T., Neeck, G., Kötter, I., Hammel, B., Amberger, C., Haus, U., Färber, L., Pongratz, D., & Müller, W.
- Venue
- Scandinavian Journal of Rheumatology
- Publisher
- Informa UK Limited
- Published
- 2004-07
- Volume
- 33
- Issue
- 4
- Pages
- 267-270
- ISSN
- 0300-9742 (ISSN-L)
- 1502-7732
- OpenAlex
- W2081817123
- Cited by
- 63
- References
- 2
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. https://app.cochat.ai/papers/10.1080/03009740410005818
- The paper
- Späth, M., Stratz, T., Neeck, G., Kötter, I., Hammel, B., Amberger, C., Haus, U., Färber, L., Pongratz, D., & Müller, W. (2004). Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scandinavian Journal of Rheumatology. https://doi.org/10.1080/03009740410005818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.